Life Sciences Opportunities in India & China: From Innovation to Commercialization
30 September 2009
China and India are emerging as major players in the life sciences industry. Both countries have a wealth of top talent as well as rapidly-improving resources for the industry. Both countries also constitute important current and potential markets for drugs, devices and diagnostics, and are also projected to be major sources of innovation in the not-too-distant future. This panel will explore the significant opportunities in China and India, in terms not only of expanding operations to both countries, but also in terms of working with innovative companies that originate from China and India.
Moderator:
- David A. Charapp, Special Counsel, Foley & Lardner LLP
Panelists:
- Stephen A. Bent, Partner, Foley & Lardner LLP
- Friedhelm Blobel, Ph.D., President, CEO, Director, SciClone Pharmaceuticals
- Kim Kamdar, Ph.D., Principal at Domain Associates
- Sanjay Shukla, M.D., M.S., Chief Executive Officer, RxMD
Related Insights
02 April 2025
Events
How Employers Can Prepare for Immigration Audits and Visits
The landscape of U.S. immigration law is constantly shifting; don't let this uncertainty impact your business.
27 March 2025
Health Care Law Today
Massachusetts: Expansion of Oversight Authority — New Notice of Material Change Form for Health Care Transactions
The Massachusetts Health Policy Commission, an independent state agency that works to improve affordability of health care for residents of the Commonwealth, released Advance Guidance for “Providers” and “Provider Organizations” considering transactions subject to the HPC’s updated Notice of Material Change process.
26 March 2025
Foley Viewpoints
Clear Terms of Franchise Agreement Are Enforced Against Franchisee
A recent federal court decision in T&T Management, Inc. v. Choice Hotels, Inc. underscores key contractual and operational considerations for franchisors.